Gastroparesis Drugs Market by Product Type (Branded, Generics), Drug Class (Dopamine Antagonists, Motilin Receptor Agonists, Serotonin Receptor Agonists), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Gastroparesis Drugs Market was valued at USD 4.54 billion in 2024 and is projected to grow to USD 4.87 billion in 2025, with a CAGR of 7.30%, reaching USD 7.97 billion by 2032.
Concise strategic framing of gastroparesis pharmacotherapy fundamentals clinical considerations and study boundaries to orient commercial and clinical decision-makers
The introduction provides a clear foundation for understanding the current dynamics shaping the gastroparesis drugs landscape and outlines the scope of the analysis. It explains the therapeutic context by framing gastroparesis as a disorder of gastric motility with heterogeneous etiology, clinical presentations, and treatment needs. Emphasis is placed on the interplay between symptomatic management, prokinetic therapy, and the evolving role of adjunctive approaches that influence prescribing patterns and patient pathways.
This section also defines the analytical boundaries used throughout the report, clarifying that the focus is on prescription pharmacotherapies addressing motility and symptomatic control rather than on surgical or device-based interventions. It highlights key clinical considerations such as safety profiles, tolerability in long-term use, drug–drug interaction risks, and administration convenience, which collectively shape product selection across inpatient, outpatient, and home-care settings.
Lastly, the introduction positions stakeholders to appreciate subsequent sections by previewing major themes: therapeutic innovation, regulatory and trade headwinds, segmentation nuances across product types and channels, and regional variations that materially affect market access and commercialization strategies. This framing primes readers to interpret insights through a lens of clinical relevance and commercial applicability.
Critical paradigm shifts reshaping therapeutic innovation regulatory expectations and delivery platforms that are redefining competitive positioning and adoption patterns
Transformative shifts in the gastroparesis treatment landscape are being driven by several converging forces that alter competitive dynamics and patient management approaches. First, there is a growing emphasis on therapies that combine meaningful symptomatic relief with favorable tolerability profiles, prompting developers to prioritize molecules that minimize central nervous system exposure and long-term adverse events. Consequently, incumbents face pressure to re-evaluate life-cycle strategies and post-marketing evidence generation to sustain clinician trust.
Second, delivery innovation is reshaping real-world adherence and route-of-administration preferences. Novel oral formulations, improved transdermal systems, and optimized injectable regimens are emerging as differentiators, especially for patient segments with complex comorbidities or variable absorption. As a result, product positioning now increasingly integrates administration convenience alongside pure efficacy claims, affecting formulary negotiations and hospital procurement decisions.
Third, regulatory scrutiny and an elevated expectation for robust safety data are prompting more comprehensive post-approval surveillance and targeted comparative-effectiveness studies. This trend incentivizes strategic partnerships between pharmaceutical sponsors and clinical networks to generate real-world evidence. Taken together, these shifts necessitate adaptive commercialization models that bridge clinical evidence, patient-centric delivery, and payer-aligned value communication to capture long-term adoption.
Strategic implications of evolving United States tariff scenarios for supply chain resilience procurement strategies and commercial prioritization across care settings
Assessing the cumulative impact of United States tariffs projected for 2025 requires a scenario-based approach that connects trade policy changes to supply chain cost structures, procurement behavior, and pricing dynamics without resorting to speculative figures. Tariff adjustments affecting active pharmaceutical ingredients, excipients, or finished products can increase landed costs for manufacturers and importers, thus injecting pressure into already margin-sensitive segments of the pharmaceutical value chain. When tariffs apply unevenly across countries of origin, manufacturers may reevaluate sourcing strategies or accelerate onshoring efforts to mitigate predictable cost volatility.
In addition, tariffs can indirectly affect distribution channel economics. Hospitals and integrated delivery networks that rely on centralized purchasing will respond to rising input costs by tightening contract terms, prioritizing therapeutically equivalent generics, or restructuring inventory policies to buffer price swings. Smaller clinics and home-care providers may experience delayed access to newer delivery forms if manufacturers redirect limited supply toward higher-margin channels. These operational adjustments can alter short-term procurement cycles and influence longer-term capital allocation decisions for inventory and supplier diversification.
Finally, tariffs can catalyze strategic responses beyond price management. Firms may pursue vertical integration, renegotiate supplier contracts, or invest in domestic manufacturing capacity to secure supply continuity. They may also intensify engagement with payers and providers to articulate clinical differentiation that justifies premium positioning despite added trade-related cost pressures. By taking a systems-level view, stakeholders can design mitigation pathways that preserve access and patient care quality while navigating evolving trade landscapes.
Nuanced segmentation-driven insights connecting product type pharmacologic class administration channel and end-user behavior to targeted commercialization pathways
Key segmentation insights synthesize how distinct product, pharmacologic, administration, distribution, and end-user slices shape clinical decision-making and commercialization tactics. Based on product type, the market’s split between Branded and Generics informs differential investment in physician education, life-cycle management, and rebate strategies, with branded products typically leveraging clinical differentiation while generics compete on price and availability. Based on drug class, therapeutic distinctions among Dopamine Antagonists, Motilin Receptor Agonists, and Serotonin Receptor Agonists create divergent safety and efficacy profiles that influence prescriber choice; Dopamine Antagonists further segment into agents such as Cisapride, Domperidone, and Metoclopramide, each associated with unique regulatory histories and tolerability trade-offs, while Motilin Receptor Agonists include compounds like Azithromycin and Erythromycin known for off-label prokinetic use, and Serotonin Receptor Agonists encompass agents such as Granisetron and Ondansetron valued for antiemetic benefits.
Based on route of administration, distinctions among Injectable, Oral, and Transdermal forms determine inpatient versus outpatient utility, adherence considerations, and manufacturing complexity, prompting targeted messaging to clinicians and pharmacists about administration advantages. Based on distribution channel, the dynamics across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy affect ordering cycles, reimbursement pathways, and promotional access, with each channel requiring a tailored commercialization approach to optimize stocking and prescribing. Based on end user, segmentation across Clinics, Home Care Settings, and Hospitals highlights heterogeneous patient management pathways, where home-care adoption emphasizes ease of use and stability while hospital settings prioritize acute efficacy and formulary alignment. Together, these segmentation lenses enable more precise targeting of clinical evidence generation, pricing strategies, and channel-specific value propositions.
Comparative regional intelligence highlighting how regulatory divergence supply chain capacity and payer dynamics influence adoption and commercialization strategies
Regional dynamics reveal differentiated clinical practices, regulatory environments, and distribution infrastructures that materially influence how therapies are adopted and scaled. In the Americas, health systems increasingly balance centralized payer negotiations with diverse private-sector delivery networks, creating both opportunities and constraints for formulary inclusion and pricing strategies; this region often emphasizes data demonstrating cost-effectiveness and real-world outcomes to secure placement and reimbursement.
In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and reimbursement approaches demands tailored market-access pathways. Regulatory authorities in some jurisdictions require extensive post-approval safety monitoring, while procurement mechanisms range from national tenders to institution-level purchasing, which affects time-to-adoption and commercialization sequencing. Furthermore, varying levels of healthcare infrastructure across subregions shape the feasibility of advanced administration forms and influence supply chain design.
In Asia-Pacific, rapid capacity expansion, rising investment in domestic manufacturing, and growing emphasis on outpatient care delivery create a dynamic environment for both branded innovation and generics competition. Local regulatory reforms that streamline approvals in certain markets can accelerate access, while other markets maintain stringent requirements that favor established therapies. Collectively, these regional contrasts necessitate differentiated launch sequencing, evidence generation strategies, and partnerships with local distributors and clinical opinion leaders to optimize uptake.
Corporate strategic postures and partnership models that combine formulation differentiation clinical evidence and supply chain scale to drive therapeutic adoption
Key companies in the gastroparesis therapeutic arena are pursuing varied strategies to secure clinical credibility and commercial traction. Some organizations prioritize differentiated formulations and novel delivery systems to address adherence and tolerability challenges, investing in clinical trials and real-world evidence programs that underscore safety and comparative effectiveness. Others focus on expanding generic portfolios and manufacturing scale to serve hospital and retail channels where price sensitivity dictates procurement decisions.
In addition, strategic collaboration is becoming a common playbook. Partnerships between pharmaceutical developers and clinical research networks enable accelerated evidence generation, while alliances with contract manufacturers and logistics providers enhance supply chain resilience. Licensing agreements and geographic distribution partnerships are also central to optimizing market access across regions with divergent regulatory and payer environments. These approaches reflect an industry balancing scientific differentiation with commercial pragmatism to meet diverse stakeholder expectations.
Finally, corporate portfolios are increasingly aligned to support multichannel distribution, with investments in digital engagement and pharmacy support programs aimed at improving adherence and patient education. By integrating clinical, operational, and commercial capabilities, companies can reinforce prescriber confidence and streamline pathways from hospital initiation to home-care maintenance.
Practical strategic guidance for manufacturers payers and providers to strengthen evidence value communication and supply resilience across evolving care pathways
Actionable recommendations for industry leaders concentrate on aligning clinical value propositions with pragmatic commercialization and supply management tactics. First, prioritize rigorous comparative-effectiveness and safety data generation to differentiate products in clinical conversations and payer negotiations; targeted real-world studies that demonstrate tolerability in routine care settings will strengthen formulary positioning and clinician confidence. Second, redesign launch sequencing to reflect channel-specific requirements, ensuring that hospital formulary campaigns, retail pharmacy stocking, and home-care distribution are coordinated to maintain continuity of access for patients transitioning across care settings.
Third, invest in supply chain flexibility by diversifying sources of active pharmaceutical ingredients and establishing contingency manufacturing relationships to reduce exposure to trade-related shocks. Fourth, refine pricing and contracting approaches to reflect channel economics and payer priorities, combining value-based narrative with practical rebate and distribution agreements that support long-term sustainability. Fifth, enhance patient and provider support programs, utilizing digital tools and targeted education to improve adherence, monitor safety signals, and capture outcomes data that feed back into credibility-building activities. Implemented together, these actions will help organizations navigate regulatory complexity, tariff headwinds, and evolving clinician expectations while preserving patient access.
Transparent multi-method research approach combining primary clinical stakeholder interviews systematic literature review and operational scenario analysis for robust insights
The research methodology underpinning this analysis integrates multiple evidence streams to deliver rigorous, actionable insights. Primary research included structured interviews with clinicians, pharmacists, payers, and supply chain professionals to capture frontline perspectives on prescribing behavior, formulary decision criteria, and procurement constraints. These qualitative inputs were complemented by a systematic review of peer-reviewed clinical literature, regulatory guidance documents, and public safety databases to validate therapeutic distinctions and safety considerations across drug classes and formulations.
Secondary analysis incorporated commercial intelligence on distribution practices, channel economics, and regional regulatory frameworks, along with case studies illustrating successful commercialization and supply chain resilience strategies. Triangulation of data sources ensured that conclusions reflect corroborated observations rather than single-source assumptions. Where appropriate, scenario analysis was used to model the operational impact of trade-related disruptions and to identify feasible mitigation pathways. Throughout, quality control measures such as expert peer review and source verification were applied to maintain analytical rigor and relevance to commercial decision-making.
Integrated strategic synthesis outlining clinical differentiation supply chain resilience and commercial alignment as prerequisites for sustainable programmatic success
The conclusion synthesizes the report’s core findings and reiterates strategic imperatives for stakeholders seeking to navigate the gastroparesis drugs landscape effectively. Innovation at the intersection of efficacy, tolerability, and administration convenience will remain the primary differentiator as clinicians and patients weigh therapeutic options. At the same time, regulatory expectations and payer scrutiny underscore the importance of credible safety and real-world performance data in securing and sustaining adoption across care settings.
Operationally, supply chain resilience and adaptive procurement strategies are essential to mitigate external shocks such as trade policy shifts. Commercial success will depend on integrated approaches that align evidence generation, channel-specific deployment, and pricing models with the realities of regional healthcare systems. By adopting a coordinated strategy that combines clinical differentiation, pragmatic commercialization, and operational flexibility, organizations can improve patient access and achieve durable uptake while responding to the evolving dynamics of the therapeutic landscape.
Note: PDF & Excel + Online Access - 1 Year
Concise strategic framing of gastroparesis pharmacotherapy fundamentals clinical considerations and study boundaries to orient commercial and clinical decision-makers
The introduction provides a clear foundation for understanding the current dynamics shaping the gastroparesis drugs landscape and outlines the scope of the analysis. It explains the therapeutic context by framing gastroparesis as a disorder of gastric motility with heterogeneous etiology, clinical presentations, and treatment needs. Emphasis is placed on the interplay between symptomatic management, prokinetic therapy, and the evolving role of adjunctive approaches that influence prescribing patterns and patient pathways.
This section also defines the analytical boundaries used throughout the report, clarifying that the focus is on prescription pharmacotherapies addressing motility and symptomatic control rather than on surgical or device-based interventions. It highlights key clinical considerations such as safety profiles, tolerability in long-term use, drug–drug interaction risks, and administration convenience, which collectively shape product selection across inpatient, outpatient, and home-care settings.
Lastly, the introduction positions stakeholders to appreciate subsequent sections by previewing major themes: therapeutic innovation, regulatory and trade headwinds, segmentation nuances across product types and channels, and regional variations that materially affect market access and commercialization strategies. This framing primes readers to interpret insights through a lens of clinical relevance and commercial applicability.
Critical paradigm shifts reshaping therapeutic innovation regulatory expectations and delivery platforms that are redefining competitive positioning and adoption patterns
Transformative shifts in the gastroparesis treatment landscape are being driven by several converging forces that alter competitive dynamics and patient management approaches. First, there is a growing emphasis on therapies that combine meaningful symptomatic relief with favorable tolerability profiles, prompting developers to prioritize molecules that minimize central nervous system exposure and long-term adverse events. Consequently, incumbents face pressure to re-evaluate life-cycle strategies and post-marketing evidence generation to sustain clinician trust.
Second, delivery innovation is reshaping real-world adherence and route-of-administration preferences. Novel oral formulations, improved transdermal systems, and optimized injectable regimens are emerging as differentiators, especially for patient segments with complex comorbidities or variable absorption. As a result, product positioning now increasingly integrates administration convenience alongside pure efficacy claims, affecting formulary negotiations and hospital procurement decisions.
Third, regulatory scrutiny and an elevated expectation for robust safety data are prompting more comprehensive post-approval surveillance and targeted comparative-effectiveness studies. This trend incentivizes strategic partnerships between pharmaceutical sponsors and clinical networks to generate real-world evidence. Taken together, these shifts necessitate adaptive commercialization models that bridge clinical evidence, patient-centric delivery, and payer-aligned value communication to capture long-term adoption.
Strategic implications of evolving United States tariff scenarios for supply chain resilience procurement strategies and commercial prioritization across care settings
Assessing the cumulative impact of United States tariffs projected for 2025 requires a scenario-based approach that connects trade policy changes to supply chain cost structures, procurement behavior, and pricing dynamics without resorting to speculative figures. Tariff adjustments affecting active pharmaceutical ingredients, excipients, or finished products can increase landed costs for manufacturers and importers, thus injecting pressure into already margin-sensitive segments of the pharmaceutical value chain. When tariffs apply unevenly across countries of origin, manufacturers may reevaluate sourcing strategies or accelerate onshoring efforts to mitigate predictable cost volatility.
In addition, tariffs can indirectly affect distribution channel economics. Hospitals and integrated delivery networks that rely on centralized purchasing will respond to rising input costs by tightening contract terms, prioritizing therapeutically equivalent generics, or restructuring inventory policies to buffer price swings. Smaller clinics and home-care providers may experience delayed access to newer delivery forms if manufacturers redirect limited supply toward higher-margin channels. These operational adjustments can alter short-term procurement cycles and influence longer-term capital allocation decisions for inventory and supplier diversification.
Finally, tariffs can catalyze strategic responses beyond price management. Firms may pursue vertical integration, renegotiate supplier contracts, or invest in domestic manufacturing capacity to secure supply continuity. They may also intensify engagement with payers and providers to articulate clinical differentiation that justifies premium positioning despite added trade-related cost pressures. By taking a systems-level view, stakeholders can design mitigation pathways that preserve access and patient care quality while navigating evolving trade landscapes.
Nuanced segmentation-driven insights connecting product type pharmacologic class administration channel and end-user behavior to targeted commercialization pathways
Key segmentation insights synthesize how distinct product, pharmacologic, administration, distribution, and end-user slices shape clinical decision-making and commercialization tactics. Based on product type, the market’s split between Branded and Generics informs differential investment in physician education, life-cycle management, and rebate strategies, with branded products typically leveraging clinical differentiation while generics compete on price and availability. Based on drug class, therapeutic distinctions among Dopamine Antagonists, Motilin Receptor Agonists, and Serotonin Receptor Agonists create divergent safety and efficacy profiles that influence prescriber choice; Dopamine Antagonists further segment into agents such as Cisapride, Domperidone, and Metoclopramide, each associated with unique regulatory histories and tolerability trade-offs, while Motilin Receptor Agonists include compounds like Azithromycin and Erythromycin known for off-label prokinetic use, and Serotonin Receptor Agonists encompass agents such as Granisetron and Ondansetron valued for antiemetic benefits.
Based on route of administration, distinctions among Injectable, Oral, and Transdermal forms determine inpatient versus outpatient utility, adherence considerations, and manufacturing complexity, prompting targeted messaging to clinicians and pharmacists about administration advantages. Based on distribution channel, the dynamics across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy affect ordering cycles, reimbursement pathways, and promotional access, with each channel requiring a tailored commercialization approach to optimize stocking and prescribing. Based on end user, segmentation across Clinics, Home Care Settings, and Hospitals highlights heterogeneous patient management pathways, where home-care adoption emphasizes ease of use and stability while hospital settings prioritize acute efficacy and formulary alignment. Together, these segmentation lenses enable more precise targeting of clinical evidence generation, pricing strategies, and channel-specific value propositions.
Comparative regional intelligence highlighting how regulatory divergence supply chain capacity and payer dynamics influence adoption and commercialization strategies
Regional dynamics reveal differentiated clinical practices, regulatory environments, and distribution infrastructures that materially influence how therapies are adopted and scaled. In the Americas, health systems increasingly balance centralized payer negotiations with diverse private-sector delivery networks, creating both opportunities and constraints for formulary inclusion and pricing strategies; this region often emphasizes data demonstrating cost-effectiveness and real-world outcomes to secure placement and reimbursement.
In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and reimbursement approaches demands tailored market-access pathways. Regulatory authorities in some jurisdictions require extensive post-approval safety monitoring, while procurement mechanisms range from national tenders to institution-level purchasing, which affects time-to-adoption and commercialization sequencing. Furthermore, varying levels of healthcare infrastructure across subregions shape the feasibility of advanced administration forms and influence supply chain design.
In Asia-Pacific, rapid capacity expansion, rising investment in domestic manufacturing, and growing emphasis on outpatient care delivery create a dynamic environment for both branded innovation and generics competition. Local regulatory reforms that streamline approvals in certain markets can accelerate access, while other markets maintain stringent requirements that favor established therapies. Collectively, these regional contrasts necessitate differentiated launch sequencing, evidence generation strategies, and partnerships with local distributors and clinical opinion leaders to optimize uptake.
Corporate strategic postures and partnership models that combine formulation differentiation clinical evidence and supply chain scale to drive therapeutic adoption
Key companies in the gastroparesis therapeutic arena are pursuing varied strategies to secure clinical credibility and commercial traction. Some organizations prioritize differentiated formulations and novel delivery systems to address adherence and tolerability challenges, investing in clinical trials and real-world evidence programs that underscore safety and comparative effectiveness. Others focus on expanding generic portfolios and manufacturing scale to serve hospital and retail channels where price sensitivity dictates procurement decisions.
In addition, strategic collaboration is becoming a common playbook. Partnerships between pharmaceutical developers and clinical research networks enable accelerated evidence generation, while alliances with contract manufacturers and logistics providers enhance supply chain resilience. Licensing agreements and geographic distribution partnerships are also central to optimizing market access across regions with divergent regulatory and payer environments. These approaches reflect an industry balancing scientific differentiation with commercial pragmatism to meet diverse stakeholder expectations.
Finally, corporate portfolios are increasingly aligned to support multichannel distribution, with investments in digital engagement and pharmacy support programs aimed at improving adherence and patient education. By integrating clinical, operational, and commercial capabilities, companies can reinforce prescriber confidence and streamline pathways from hospital initiation to home-care maintenance.
Practical strategic guidance for manufacturers payers and providers to strengthen evidence value communication and supply resilience across evolving care pathways
Actionable recommendations for industry leaders concentrate on aligning clinical value propositions with pragmatic commercialization and supply management tactics. First, prioritize rigorous comparative-effectiveness and safety data generation to differentiate products in clinical conversations and payer negotiations; targeted real-world studies that demonstrate tolerability in routine care settings will strengthen formulary positioning and clinician confidence. Second, redesign launch sequencing to reflect channel-specific requirements, ensuring that hospital formulary campaigns, retail pharmacy stocking, and home-care distribution are coordinated to maintain continuity of access for patients transitioning across care settings.
Third, invest in supply chain flexibility by diversifying sources of active pharmaceutical ingredients and establishing contingency manufacturing relationships to reduce exposure to trade-related shocks. Fourth, refine pricing and contracting approaches to reflect channel economics and payer priorities, combining value-based narrative with practical rebate and distribution agreements that support long-term sustainability. Fifth, enhance patient and provider support programs, utilizing digital tools and targeted education to improve adherence, monitor safety signals, and capture outcomes data that feed back into credibility-building activities. Implemented together, these actions will help organizations navigate regulatory complexity, tariff headwinds, and evolving clinician expectations while preserving patient access.
Transparent multi-method research approach combining primary clinical stakeholder interviews systematic literature review and operational scenario analysis for robust insights
The research methodology underpinning this analysis integrates multiple evidence streams to deliver rigorous, actionable insights. Primary research included structured interviews with clinicians, pharmacists, payers, and supply chain professionals to capture frontline perspectives on prescribing behavior, formulary decision criteria, and procurement constraints. These qualitative inputs were complemented by a systematic review of peer-reviewed clinical literature, regulatory guidance documents, and public safety databases to validate therapeutic distinctions and safety considerations across drug classes and formulations.
Secondary analysis incorporated commercial intelligence on distribution practices, channel economics, and regional regulatory frameworks, along with case studies illustrating successful commercialization and supply chain resilience strategies. Triangulation of data sources ensured that conclusions reflect corroborated observations rather than single-source assumptions. Where appropriate, scenario analysis was used to model the operational impact of trade-related disruptions and to identify feasible mitigation pathways. Throughout, quality control measures such as expert peer review and source verification were applied to maintain analytical rigor and relevance to commercial decision-making.
Integrated strategic synthesis outlining clinical differentiation supply chain resilience and commercial alignment as prerequisites for sustainable programmatic success
The conclusion synthesizes the report’s core findings and reiterates strategic imperatives for stakeholders seeking to navigate the gastroparesis drugs landscape effectively. Innovation at the intersection of efficacy, tolerability, and administration convenience will remain the primary differentiator as clinicians and patients weigh therapeutic options. At the same time, regulatory expectations and payer scrutiny underscore the importance of credible safety and real-world performance data in securing and sustaining adoption across care settings.
Operationally, supply chain resilience and adaptive procurement strategies are essential to mitigate external shocks such as trade policy shifts. Commercial success will depend on integrated approaches that align evidence generation, channel-specific deployment, and pricing models with the realities of regional healthcare systems. By adopting a coordinated strategy that combines clinical differentiation, pragmatic commercialization, and operational flexibility, organizations can improve patient access and achieve durable uptake while responding to the evolving dynamics of the therapeutic landscape.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
199 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increasing adoption of novel ghrelin receptor agonists demonstrating improved gastric motility in refractory gastroparesis patients
- 5.2. Emerging use of noninvasive gastric electrical stimulation devices for outpatient management of diabetic gastroparesis symptoms
- 5.3. Advancements in formulation of sustained release metoclopramide to minimize central nervous system side effects in long term therapy
- 5.4. Rising investment in oral small molecule prokinetics targeting multiple receptor pathways to overcome current therapeutic limitations
- 5.5. Integration of real world evidence from patient registries to support reimbursement of high cost gastroparesis biologic therapies
- 5.6. Expansion of pipeline trials assessing combination therapies of serotonergic and motilin analogs for synergistic prokinetic effects
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Gastroparesis Drugs Market, by Product Type
- 8.1. Branded
- 8.2. Generics
- 9. Gastroparesis Drugs Market, by Drug Class
- 9.1. Dopamine Antagonists
- 9.1.1. Cisapride
- 9.1.2. Domperidone
- 9.1.3. Metoclopramide
- 9.2. Motilin Receptor Agonists
- 9.2.1. Azithromycin
- 9.2.2. Erythromycin
- 9.3. Serotonin Receptor Agonists
- 9.3.1. Granisetron
- 9.3.2. Ondansetron
- 10. Gastroparesis Drugs Market, by Route Of Administration
- 10.1. Injectable
- 10.2. Oral
- 10.3. Transdermal
- 11. Gastroparesis Drugs Market, by End User
- 11.1. Clinics
- 11.2. Home Care Settings
- 11.3. Hospitals
- 12. Gastroparesis Drugs Market, by Distribution Channel
- 12.1. Hospital Pharmacy
- 12.2. Online Pharmacy
- 12.3. Retail Pharmacy
- 13. Gastroparesis Drugs Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Gastroparesis Drugs Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Gastroparesis Drugs Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Abbott Laboratories
- 16.3.2. AbbVie Inc.
- 16.3.3. Amneal Pharmaceuticals, Inc.
- 16.3.4. ANI Pharmaceuticals, Inc.
- 16.3.5. AstraZeneca PLC
- 16.3.6. Atlantic Healthcare PLC
- 16.3.7. Bausch Health Companies Inc.
- 16.3.8. Bristol-Myers Squibb Company
- 16.3.9. Cadila Pharmaceuticals Limited
- 16.3.10. Cairn Diagnostics
- 16.3.11. Evoke Pharma, Inc.
- 16.3.12. GlaxoSmithKline PLC
- 16.3.13. Johnson & Johnson Services, Inc.
- 16.3.14. Kyowa Kirin International plc
- 16.3.15. Lupin Limited
- 16.3.16. Medtronic PLC
- 16.3.17. Neurogastrx, Inc.
- 16.3.18. Novartis AG
- 16.3.19. Pfizer, Inc.
- 16.3.20. Processa Pharmaceuticals, Inc.
- 16.3.21. Sanofi S.A.
- 16.3.22. Takeda Pharmaceutical Company Limited
- 16.3.23. Theravance Biopharma
- 16.3.24. Vanda Pharmaceuticals Inc.
- 16.3.25. Viatris Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
